Clinical trials: Advanced Malignant Solid Tumours
Malignant Solid Tumour
BN80927 in Patients With Advanced Malignant Solid Tumors
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
- Trial name
- NCT01435096
- Testing
- BN80927
- Where
- 3 sites in France
- Volunteers
- 56 people
- Sponsor
- Ipsen
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Malignant Solid Tumor, Lymphomas
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies.
- Trial name
- DINAMIC (NCT01359982)
- Testing
- RRx-001
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- EpicentRx, Inc.
Advanced Malignant Solid Tumors
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to…
- Trial name
- NCT05338957
- Testing
- MRG002+HX008
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Miracogen Inc.
Advanced Malignant Solid Tumor
A Study of JSKN027 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase 1 (Ia/Ib) clinical study conducted in China to evaluate the safety and tolerability of JSKN027 in patients with advanced malignant solid tumors.
- Trial name
- NCT07391644
- Testing
- JSKN027
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Neoplasm Malignant
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity…
- Trial name
- NCT06238687
- Testing
- STRO-002
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Advanced Cancer
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of NTKR-214 in combination with nivolumab in Japanese participants with advanced malignant tumors.
- Trial name
- NCT03745807
- Testing
- NKTR-214, Nivolumab
- Where
- Japan
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Cancer, Non Small Cell Lung Cancer
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies.
- Conditions
- Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
- Trial name
- NCT03917043
- Testing
- APG-2449
- Where
- 9 sites in China
- Volunteers
- 165 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Solid Tumors
A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors
This a multi-center, open-label, non-randomized phaseⅠb trail. The purpose of this study was to evaluate the efficacy and safety of QL1706 in patients with advanced solid tumors and to investigate the immunogenicity and…
- Trial name
- NCT05171790
- Testing
- QL1706 injection
- Where
- China
- Volunteers
- 419 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor
BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
This is a multi-center, open-label, Phase I/II clinical study of BPB-101 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of BPB-101.
- Trial name
- NCT05869240
- Testing
- BPB-101
- Where
- 4 sites in China
- Volunteers
- 388 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer
- Trial name
- NCT02440685
- Testing
- ASN002 Dose Escalation, ASN002 RD
- Where
- 14 sites in United States, Argentina
- Volunteers
- 51 people
- Sponsor
- Asana BioSciences
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of SGN-ALPV in Advanced Solid Tumors
This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms
- Trial name
- NCT05229900
- Testing
- SGN-ALPV
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 43 people
- Sponsor
- Seagen Inc.
Neoplasm Malignant
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Primary Objectives: To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment To determine the pharmacokinetics (PKs) of…
- Trial name
- NCT01140607
- Testing
- Cabazitaxel (XRP6258)
- Where
- 14 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sanofi
Solid Tumors
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
This is a Phase I, open-label, multicenter, dose-escalation study designed to assess the safety and tolerability of Genz-644282, administered as an intravenous (IV) infusion, to patients with advanced malignant solid tumors.
- Trial name
- NCT00942799
- Testing
- Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule)
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Genzyme, a Sanofi Company
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Biliary Tract Cancer, Melanoma
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma
- Trial name
- NCT06708663
- Testing
- HX009+IN10018
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Advanced Solid Tumors, Metastatic Solid Tumors
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in subjects with advanced inoperable or metastatic…
- Trial name
- NCT05494918
- Testing
- JSKN003
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alphamab (Australia) Co Pty Ltd.
Advanced Malignant Solid Tumor
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors.
- Trial name
- NCT04165590
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Advanced Solid Tumors
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
An Open-label, Single-arm, Phase I Clinical Study of GK01 Cell Injection in the Treatment of Patients with Advanced Malignant Solid Tumors
- Trial name
- NCT07482319
- Testing
- GK01 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Geekgene Technology Co., LTD